AbbVie Inc.
Market Data Current As Of: September 12, 2026
Related Competitor Intelligence
Compare market positioning with top industry peers
Explore AbbVie
Core profile pages, annual revenue records, and related research hubs for this company.
AbbVie Inc.
Compare market positioning with top industry peers
Explore AbbVie
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$61.2B (FY2025)
Market Cap
$312.4B
Net Income
$4.2B
Employees
50,034
AbbVie has executed one of the most successful pharmaceutical patent-cliff transitions in modern history. Following the loss of exclusivity for Humira (historically the world's best-selling drug), AbbVie's financial narrative in 2026 is defined by the explosive growth of its immunology successors, Skyrizi and Rinvoq. Under CEO Robert A. Michael, the company commands a $312.4 billion market cap and generates over $55.3 billion in revenue. AbbVie has utilized the cash flow from its aesthetics division (Botox) to fund aggressive M&A, including the multi-billion dollar acquisition of ImmunoGen to bolster its oncology pipeline with advanced antibody-drug conjugates (ADCs).
Revenue Trend Analysis
YoY Change
+8.6%
5-Year CAGR
+6%
Peak Year
2025
Trend
Consistent Growth
AbbVie Inc. has reported revenue across 6 fiscal years, compounding at +6% annually over 5 years. The most recent year saw a 8.6% increase versus the prior year. Revenue peaked in 2025 at $61.2B. Out of 5 reported periods, 4 showed growth and 1 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $61.2B | $4.2B | +8.6% |
| FY2024 | $56.3B | — | +3.7% |
| FY2023 | $54.3B | — | -6.4% |
| FY2022 | $58.1B | — | +3.3% |
| FY2021 | $56.2B | — | +22.7% |
| FY2020 | $45.8B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
AbbVie Inc. reported approximately $55.3B in fiscal year 2025 with a team of 50,034 employees worldwide.
AbbVie Inc. strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Biopharmaceutical is driven by steady cash generation and pricing power, enabling AbbVie Inc. to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "AbbVie Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/abbvie/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>AbbVie Inc. reported $61B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/abbvie/financials" target="_blank" rel="noopener">CorpDigest — AbbVie Inc. financials</a></div>